Idarubicine
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Bruno C. MedeirosPhase 2Dormant
BBB
76/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 64/ 100
- Competitive Position
- 95/ 100
Competitive context
8 Active assets in the Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Daunorubicin National Cancer Institute (NCI) | Phase 3 | BBB |
Cytosin-Arabinosid Alice Mims | Phase 3 | BBB |
Fludarabine Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 | BBB |
ETOPOSIDE Alice Mims | Phase 3 | BBB |
Azacitidine The First Affiliated Hospital of Soochow University | Phase 2 | BBB |
View all 50 →
Same molecule, other indications
Idarubicine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →